Novo Nordisk has rebounded over 40% after a sharp 2025 sell-off, driven by renewed optimism for its oral Wegovy launch. Click ...
Eli Lilly looks undervalued as earnings forecasts rise and GLP-1 catalysts near. Read the full analysis here of LLY stock.
Medicare plans to cap costs for GLP-1 weight-loss drugs like Wegovy at about $50 a month under a new agreement set to launch ...
This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback